Aurobindo Pharma Limited has informed the Exchange about Acquisition
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aurobindo Pharma's US arm, Aurobindo Pharma USA Inc., has signed a definitive agreement to buy 100% of Lannett Company LLC, a US-based generic pharmaceutical maker founded in 1942 and headquartered in Trevose, Pennsylvania. The deal is valued at US$250 million (about ₹2,185 crore) in cash on a debt-free, cash-free basis, translating to a 0.82x sales multiple. Lannett reported revenue of around $300 million (TTM FY25: $306 mn) and specializes in complex generics, generic liquids, and non-opioid controlled substances, particularly ADHD treatments. The acquisition gives Aurobindo a 425,000 sq ft US manufacturing facility in Seymour, Indiana, with annual capacity of about 3.6 billion doses, currently running at only 40% utilization. The deal is expected to close in 8–12 months subject to US FTC approval and is projected to be EPS accretive by around ₹5 per share.
This is a strategic, EPS-accretive acquisition that strengthens Aurobindo's US manufacturing presence, adds a profitable complex generics and CDMO business, and provides significant excess capacity for future growth — likely viewed positively by investors, though the $250 million cash outflow and regulatory uncertainty are key watchpoints.